Paper10604231
Phage therapy: past history and future prospects.
Carlton RM. Arch Immunol Ther Exp (Warsz), 1999. Cited by 191 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Phage therapy: past history and future prospects. Papers, record 10604231. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10604231
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacterial Infections | Major topic |
| Bacteriophages | Major topic |
| Administration, Oral | |
| Animals | |
| Anti-Bacterial Agents | |
| Antibodies, Viral | |
| Bacteremia | |
| Bacteriophage lambda | |
| Chickens | |
| Clinical Trials as Topic | |
| Combined Modality Therapy | |
| Drug Resistance, Microbial | |
| Drug Resistance, Multiple | |
| Escherichia coli Infections | |
| Europe, Eastern | |
| Forecasting | |
| Genetic Engineering | |
| Humans | |
| Lysogeny | |
| Metabolic Clearance Rate | |
| Mice | |
| Pharmacokinetics | |
| Rabbits | |
| Rats | |
| Research Design | |
| Therapeutics | |
| Treatment Outcome |
Source PubMed
Cited by109
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 191 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,305,429 | Potential Vaccine or Antimicrobial Reagents: Simple Systems for Producing Lambda Display Particles (LDP) and Sheathed Lambda DNA Vaccine Particles (LDNAP). | Viruses | 2025 | https://conductscience.org/library/papers/41305429 | PubMed |
| 41,159,315 | From plaques to pocks: carrying over bacteriophage assay techniques to the study of influenza and other animal viruses. | Med Hist | 2026 | https://conductscience.org/library/papers/41159315 | PubMed |
| 40,426,525 | Isolation and Genomic Analysis of Escherichia coli Phage AUBRB02: Implications for Phage Therapy in Lebanon. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40426525 | PubMed |
| 40,045,606 | Effects of bacteriophage cocktail supplementation in gestation diet on reproductive performance, blood profile, milk composition, and fecal microflora of sows. | Anim Biosci | 2025 | https://conductscience.org/library/papers/40045606 | PubMed |
| 39,728,014 | Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections. | Infect Dis Rep | 2024 | https://conductscience.org/library/papers/39728014 | PubMed |
| 39,452,186 | Beyond Antibiotics: What the Future Holds. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39452186 | PubMed |
| 39,338,470 | The Potential of Phage Treatment to Inactivate Planktonic and Biofilm-Forming Pseudomonas aeruginosa. | Microorganisms | 2024 | https://conductscience.org/library/papers/39338470 | PubMed |
| 39,205,249 | Characterization and Anti-Biofilm Activity of Lytic Enterococcus Phage vB_Efs8_KEN04 against Clinical Isolates of Multidrug-Resistant Enterococcus faecalis in Kenya. | Viruses | 2024 | https://conductscience.org/library/papers/39205249 | PubMed |
| 38,919,495 | The trade-off of Vibrio parahaemolyticus between bacteriophage resistance and growth competitiveness. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38919495 | PubMed |
| 37,928,478 | Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37928478 | PubMed |
| 37,790,805 | Case report: Successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37790805 | PubMed |
| 37,764,155 | The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era. | Microorganisms | 2023 | https://conductscience.org/library/papers/37764155 | PubMed |
| 37,579,848 | The characterization and genome analysis of a novel phage phiA034 targeting multiple species of Aeromonas. | Virus Res | 2023 | https://conductscience.org/library/papers/37579848 | PubMed |
| 37,545,854 | Isolation and characterization of a novel mycobacteriophage Kashi-VT1 infecting Mycobacterium species. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37545854 | PubMed |
| 37,500,690 | Effects of bacteriophage on Salmonella Enteritidis infection in broilers. | Sci Rep | 2023 | https://conductscience.org/library/papers/37500690 | PubMed |
| 37,404,162 | Class-Driven Synergy and Antagonism between a Pseudomonas Phage and Antibiotics. | Infect Immun | 2023 | https://conductscience.org/library/papers/37404162 | PubMed |
| 36,978,455 | Detection and Level Evaluation of Antibodies Specific to Environmental Bacteriophage I11mO19 and Related Coliphages in Non-Immunized Human Sera. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978455 | PubMed |
| 35,631,831 | Incorporation of Mycobacteriophage Fulbright into Polycaprolactone Electrospun Nanofiber Wound Dressing. | Polymers (Basel) | 2022 | https://conductscience.org/library/papers/35631831 | PubMed |
| 34,938,668 | Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/34938668 | PubMed |
| 34,759,899 | vB-ApyS-JF1, the First Trueperella pyogenes Phage, Shows Potential as an Alternative Treatment Strategy for Trueperella pyogenes Infections. | Front Microbiol | 2021 | https://conductscience.org/library/papers/34759899 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10604231
GET https://conductscience.org/api/papers/v1/10604231/cited_by?page=2